Trial Profile
Preventing postoperative nausea and vomiting: Effect of Neurokinin-1 receptor antagonist(Fosaprepitant)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jul 2015
Price :
$35
*
At a glance
- Drugs Fosaprepitant (Primary)
- Indications Postoperative nausea and vomiting
- Focus Therapeutic Use
- 17 Oct 2013 Planned number of patients changed from 100 to 200 as reported by University Hospital Medical Information Network - Japan.
- 18 May 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 02 Apr 2012 New trial record